Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
… And Seals Antibiotics Pact With FOB
by Lisa M. Jarvis
February 3, 2014
| A version of this story appeared in
Volume 92, Issue 5
AstraZeneca and FOB Synthesis, a Kennesaw, Ga.-based custom synthesis and antibiotic development firm, will work together to develop combination therapy antibiotics to address drug-resistant infections. The companies will potentially combine AstraZeneca’s preclinical β-lactamase inhibitor (BLI) with carbapenem antibiotics in preclinical studies at FOB. AstraZeneca will develop combinations of its BLI with FOB’s FSI-1671 and FSI-1686 through Phase I, after which it has an option to license the compounds. Financial terms of the deal were not disclosed.
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X